Hepatic Steatosis Associated With Exposure to Elvitegravir and Raltegravir-Reference-Cited by-同舟云学术

Hepatic Steatosis Associated With Exposure to Elvitegravir and Raltegravir

Published:2021-01-25 Issue:3 Volume:73 Page:e811-e814
ISSN:1058-4838
Container-title:Clinical Infectious Diseases
language:en
Short-container-title:

Author:

Kirkegaard-Klitbo Ditte Marie¹,Thomsen Magda Teresa²,Gelpi Marco²,Bendtsen Flemming³⁴,Nielsen Susanne Dam²⁴,Benfield Thomas¹⁴

Affiliation:

1. CREDID, Department of Infectious Diseases, Copenhagen University Hospital, Amager and Hvidovre, Hvidovre, Denmark

2. Viro-immunology Research Unit, Department of Infectious Diseases, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark

3. Gastrounit, Medical Division, Copenhagen University Hospital, Amager and Hvidovre, Hvidovre, Denmark

4. Institute of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark

Abstract

Abstract Moderate-to-severe hepatic steatosis in people living with human immunodeficiency virus (HIV) without viral hepatitis or excessive alcohol intake was associated with cumulative exposure to stavudine, elvitegravir, and raltegravir. Prospective trials are required to establish a causal association. Clinical Trials Registration. NCT02382822.

Funder

Novo Nordisk Foundation

Lundbeck Foundation

Rigshospitalet Research Council

Region Hovedstaden

Danish National Research Foundation

Publisher

Oxford University Press (OUP)

Subject

Infectious Diseases,Microbiology (medical)

Link

http://academic.oup.com/cid/advance-article-pdf/doi/10.1093/cid/ciab057/37376944/ciab057.pdf